Allovir Inc expected to post a loss of 80  cents a share - Earnings Preview

Kalaris Therapeutics

02/05/2022 19:34

* Allovir Inc  ALVR.OQ   ALVR.O  is expected to show no
change in
quarterly revenue when it reports  results on May 4
(estimated). 
    * ​Refinitiv's mean analyst estimate for Allovir Inc is for
a loss
of 80 cents per share. For the same quarter last year, the
company reported a loss of 50 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Allovir Inc
is
$32.5​, above​ its last closing price of $4.55. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.78       -0.81      -0.92     Missed  -13.1
 Sep. 30 2021  -0.58       -0.55      -0.72     Missed  -30.9
 Jun. 30 2021  -0.54       -0.49      -0.60     Missed  -22.4​
 Mar. 31 2021  -0.40       -0.40      -0.50     Missed  -24.2
 ​​Dec.        -0.42       -0.42      -0.34     Beat    19
 31 2020                                                
 Sep. 30 2020  -0.30       -0.30      -0.58     Missed  -93.3​
 This summary was machine generated May 2 at 18:33 GMT.  All
figures in US dollars  unless otherwise stated